Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with neoadjuvant endocrine therapy (NET) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), lymph node (LN)-positive, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwark, Sungchan, Noh, Woo Chul, Ahn, Sei Hyun, Lee, Eun Sook, Jung, Yongsik, Kim, Lee Su, Han, Wonshik, Nam, Seok Jin, Gong, Gyungyub, Kim, Seon-Ok, Kim, Hee Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515848/
https://www.ncbi.nlm.nih.gov/pubmed/34660302
http://dx.doi.org/10.3389/fonc.2021.741120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515848/
https://www.ncbi.nlm.nih.gov/pubmed/34660302
http://dx.doi.org/10.3389/fonc.2021.741120

Ejemplares similares